Join to View Full Profile
9400 Campus Point DrLa Jolla, CA 92037
Phone+1 858-249-3249
Dr. Yeung is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Board-certified medical oncologist who specializes in the treatment of breast cancer within the UC San Diego Moores Cancer Center Comprehensive Breast Health Center, a NCI-designated Comprehensive Cancer Center in San Diego.
Physician-scientist whose research focuses on breast cancer, including understanding the mechanism of breast tumor dormancy and investigating clinical prognostic value of molecular profiling of circulating tumor cells.
Education & Training
University of California (San Diego) Medical CenterFellowship, Hematology and Medical Oncology, 2015 - 2017- University of California (San Diego) Medical CenterResidency, Internal Medicine, 2012 - 2014
New York University School of MedicineClass of 2012
Certifications & Licensure
CA State Medical License 2013 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer Start of enrollment: 2022 Feb 02
- A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer Start of enrollment: 2021 Sep 15
- A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer Start of enrollment: 2022 Mar 07
Publications & Presentations
PubMed
- The Hallmarks of Predictive Oncology.Akshat Singhal, Xiaoyu Zhao, Patrick Wall, Emily So, Guido Calderini
Cancer Discovery. 2025-02-07 - 4 citationsDatopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.Katia Khoury, Jane L Meisel, Christina Yau, Hope S Rugo, Rita Nanda
Nature Medicine. 2024-12-01 - 10 citationsDatopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.Rebecca A Shatsky, Meghna S Trivedi, Christina Yau, Rita Nanda, Hope S Rugo
Nature Medicine. 2024-12-01
Grant Support
- Breast Cancer Research Program Breakthrough Fellowship AwardDepartment of Defense2017–2020
Professional Memberships
- Member
- Member
Other Languages
- Chinese (Cantonese), Chinese (Mandarin)
External Links
- UC San Diego Health Provider Profilehttps://providers.ucsd.edu/details/32947/kay-yeung-cancer-la_jolla
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
